Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk

Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.

Q2 written on a speechbubble

Pfizer Inc. CEO Ian Read may have as much insight as anyone in the pharma world into US President Donald Trump's thinking on drug pricing and potential policy steps, after talking to the president on the phone and visiting him at the White House in July.

You can bet analysts and investors will want to hear what Read learned from his meeting with Trump and why...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip